Cholestyramine Pellets for Colon-Targeted Bile Acid Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cholestyramine formulations for treating bile acid malabsorption are limited by high doses, gastrointestinal side effects, drug interactions, and poor patient compliance due to taste and texture issues, as well as malabsorption of fats and fat-soluble vitamins, necessitating a more stable and targeted delivery system.
Innovation Solution
Development of small, stable cholestyramine pellets with high cholestyramine content, prepared by extrusion using a mixture of cholestyramine and vinylpyrrolidone-based polymers, acrylate copolymers, and microcrystalline cellulose, which are coated for colon-targeted release to minimize side effects and interactions, and improve patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of cholestyramine are administered to treat bile acid malabsorption, then the therapeutic effect is improved, but gastrointestinal side effects and drug interactions increase
Solution Approach 1:
The invention divides the cholestyramine dosage into multiple small pellets (each containing 5-50 mg) rather than administering a single large dose. This segmentation allows the total therapeutic dose to be distributed across many small units, reducing local concentration effects that cause gastrointestinal irritation while maintaining overall therapeutic efficacy through cumulative binding action throughout the gastrointestinal tract.
Solution Approach 2:
The pellets are designed with non-aqueous coating layers that create different functional zones: an uncoated or lightly coated core region for bile acid binding, and coated surface regions that provide protective and functional properties. This local quality differentiation allows the inner core to perform therapeutic binding while the outer coating reduces gastrointestinal side effects and controls drug release.
2Reliability
If conventional cholestyramine formulations are used, then bile acid binding is achieved, but patient compliance deteriorates due to taste and texture issues
Solution Approach 1:
Each cholestyramine pellet is coated with one or more thin non-aqueous coating layers that encapsulate the bitter-tasting cholestyramine resin. These coating films act as barriers that prevent direct contact between the resin and oral cavity, masking the unpleasant taste and improving texture, thereby enhancing patient compliance while preserving the underlying bile acid binding functionality.
Solution Approach 2:
The pellets consist of composite structures combining cholestyramine resin with coating materials such as hydrophobic polymers, waxes, or fatty acids. This composite material approach creates a multi-layered pellet where the cholestyramine core provides therapeutic function and the coating materials provide sensory improvement and controlled release properties.
3Reliability
If cholestyramine is administered in conventional forms, then bile acid malabsorption is treated, but malabsorption of fats and fat-soluble vitamins occurs
Solution Approach 1:
The non-aqueous coating layers on the pellets provide dynamic control over cholestyramine release. The coatings are designed to dissolve or erode at specific rates in the gastrointestinal environment, controlling when and where the active cholestyramine becomes available for bile acid binding. This dynamic release control allows selective binding of bile acids while permitting adequate absorption of fats and fat-soluble vitamins by timing the binding action to occur after these nutrients have been absorbed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable cholestyramine pellets with high cholestyramine content and targeted release formulation reduce gastrointestinal side effects, minimize drug interactions, and enhance patient compliance by allowing lower doses and improved delivery directly to the colon, effectively binding excess bile acids without affecting fat and vitamin absorption.
Implementation Method 1
Cholestyramine (or colestyramine; CAS Number 11041-12-6) is a strongly basic anion-exchange resin that is practically insoluble in water and is not absorbed from the gastrointestinal tract. Instead, it absorbs and combines with the bile acids in the intestine to form an insoluble complex.
Implementation Method 2
small cholestyramine pellets that can be prepared by extrusion
Data Source
AI summary
The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.